Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b

Barry A. Schechter, Aaleya F. Koreishi, Carol Karp, William J Feuer

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objective: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b. Design: Retrospective, noncomparative, interventional case series. Participants: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved. Methods: Patients' charts and clinical photographs were reviewed, and data were analyzed. Main Outcome Measures: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution. Results: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%). One of the 28 eyes treated (3.6%) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7%) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication. Conclusions: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.

Original languageEnglish
JournalOphthalmology
Volume115
Issue number8
DOIs
StatePublished - Aug 1 2008

Fingerprint

interferon alfa-2b
Neoplasms
Recurrence
Conjunctivitis
Hyperemia

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b. / Schechter, Barry A.; Koreishi, Aaleya F.; Karp, Carol; Feuer, William J.

In: Ophthalmology, Vol. 115, No. 8, 01.08.2008.

Research output: Contribution to journalArticle

Schechter, Barry A. ; Koreishi, Aaleya F. ; Karp, Carol ; Feuer, William J. / Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b. In: Ophthalmology. 2008 ; Vol. 115, No. 8.
@article{f058182ad8fd48aebaa21e9dfdd81920,
title = "Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b",
abstract = "Objective: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b. Design: Retrospective, noncomparative, interventional case series. Participants: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved. Methods: Patients' charts and clinical photographs were reviewed, and data were analyzed. Main Outcome Measures: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution. Results: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4{\%}). One of the 28 eyes treated (3.6{\%}) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7{\%}) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12{\%}). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication. Conclusions: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.",
author = "Schechter, {Barry A.} and Koreishi, {Aaleya F.} and Carol Karp and Feuer, {William J}",
year = "2008",
month = "8",
day = "1",
doi = "10.1016/j.ophtha.2007.10.039",
language = "English",
volume = "115",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Long-term Follow-up of Conjunctival and Corneal Intraepithelial Neoplasia Treated with Topical Interferon Alfa-2b

AU - Schechter, Barry A.

AU - Koreishi, Aaleya F.

AU - Karp, Carol

AU - Feuer, William J

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Objective: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b. Design: Retrospective, noncomparative, interventional case series. Participants: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved. Methods: Patients' charts and clinical photographs were reviewed, and data were analyzed. Main Outcome Measures: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution. Results: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%). One of the 28 eyes treated (3.6%) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7%) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication. Conclusions: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.

AB - Objective: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b. Design: Retrospective, noncomparative, interventional case series. Participants: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved. Methods: Patients' charts and clinical photographs were reviewed, and data were analyzed. Main Outcome Measures: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution. Results: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%). One of the 28 eyes treated (3.6%) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7%) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication. Conclusions: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.

UR - http://www.scopus.com/inward/record.url?scp=48149112772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149112772&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2007.10.039

DO - 10.1016/j.ophtha.2007.10.039

M3 - Article

C2 - 18187195

AN - SCOPUS:48149112772

VL - 115

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 8

ER -